Altimmune announced that it has signed a manufacturing agreement with Summit Biosciences for a multidose version of Altimmune’s AdCOVID intranasal vaccine against COVID-19. The announcement comes shortly after Altimmune announced an agreement with Lonza for manufacturing of the single dose version of the vaccine in a dedicated suite at Lonza’s Texas facility. A Phase 1 trial of the single dose version of AdCOVID is currently underway.
Altimmune President and CEO Vipin K. Garg commented, “As we continue to build our manufacturing consortium and progress the development of AdCOVID, we are pleased to partner with Summit Biosciences to manufacture AdCOVID in a customized multidose nasal spray delivery device. We expect this device may be a convenient and efficient option when vaccinating patients in high-demand settings where our vaccine candidate’s anticipated room temperature stability profile will also be important. In addition, Altimmune will continue to produce a single dose presentation of AdCOVID to provide alternative forms of administration. Summit Biosciences has expertise in intranasal product innovation, and we are excited to align with their highly experienced team in our fight against COVID-19.”
Summit Biosciences President and Chief Operating Officer Gregory Plucinski said, “I am pleased that Altimmune, a recognized leader in intranasal vaccine development, selected Summit in this exciting endeavor. Summit has a proven track record in bringing nasal spray medicines from concept to market with its state-of-the-art capabilities that are ideal for this program. Together, we will combine our respective expertise and capabilities with the goal of ultimately introducing a potentially novel, needle-free, nasal spray vaccine for the SARS-CoV-2 pandemic.”
Altimmune’s IND for the Phase 1 trial of AdCOVID was cleared by the FDA in February 2021. According to the company, the trial is enrolling healthy volunteers aged 18 to 55 who will receive one of three dose levels of AdCOVID. Data from the trial are expected to be available in the second quarter of 2021.
Read the Altimmune press release.
